Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction (TESLA RCT)

NCT06671418 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT06671418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06671418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction (TESLA RCT)
Lead sponsor
Erasmus Medical Center
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
August 9, 2023
Completion date
November 1, 2027
Enrollment
148 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma non-resectable, gall bladder cancer, liver metastasis, malignant hilar stricture